We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.99B
AUM Growth
+$404M
Cap. Flow
-$70.3M
Cap. Flow %
-2.35%
Top 10 Hldgs %
40.51%
Holding
78
New
15
Increased
15
Reduced
16
Closed
18

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$140M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$48M
3
ABVX
Abivax
ABVX
+$43.8M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$42.2M
5
TRML
Tourmaline Bio
TRML
+$36.3M

Top Sells

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
2
GPCR icon
Structure Therapeutics
GPCR
+$92.6M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$75.9M
4
IMVT icon
Immunovant
IMVT
+$66.2M
5
NVCR icon
NovoCure
NVCR
+$40.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
1
Insmed
INSM
$21.4B
$166M 5.54%
5,350,000
-650,000
-11% -$16.9M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$148M 4.95%
4,063,676
+517,241
+15% +$13.5M
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$143M 4.78%
2,000,000
-600,000
-23% -$34.5M
GH icon
4
Guardant Health
GH
$21.7B
$135M 4.52%
5,000,000
+950,000
+23% +$24.9M
ARGX icon
5
argenx
ARGX
$54.6B
$114M 3.81%
+300,000
New +$140M
CYTK icon
6
CALL
Cytokinetics
CYTK
$10.5B
$112M 3.76%
+1,347,300
New +$48.8M
ALKS icon
7
Alkermes
ALKS
$8.22B
$111M 3.71%
4,000,000
+200,000
+5% +$5.2M
PLRX icon
8
Pliant Therapeutics
PLRX
$64.4M
$104M 3.48%
5,750,000
+250,000
+5% +$3.8M
DVAX
9
DELISTED
Dynavax Technologies
DVAX
$99.2M 3.31%
7,093,214
+336,258
+5% +$4.67M
AXSM icon
10
Axsome Therapeutics
AXSM
$11.2B
$79.6M 2.66%
1,000,000
-140,745
-12% -$9.41M
VRDN icon
11
Viridian Therapeutics
VRDN
$2.09B
$79.1M 2.64%
3,631,728
+668,461
+23% +$10.6M
AUTL
12
Autolus Therapeutics
AUTL
$407M
$76.4M 2.55%
11,869,297
-3,130,703
-21% -$11.9M
PACB icon
13
Pacific Biosciences
PACB
$435M
$68.7M 2.29%
7,000,000
+1,000,000
+17% +$8.18M
NTLA icon
14
Intellia Therapeutics
NTLA
$1.49B
$68.6M 2.29%
2,250,000
+250,000
+13% +$7.18M
TVTX icon
15
Travere Therapeutics
TVTX
$5.2B
$66.3M 2.21%
7,370,000
– –
APGE icon
16
Apogee Therapeutics
APGE
$10.1B
$64.9M 2.17%
2,323,456
-90,917
-4% -$1.82M
VRNA
17
DELISTED
Verona Pharma
VRNA
$63.4M 2.12%
3,187,415
– –
IONS icon
18
Ionis Pharmaceuticals
IONS
$8.6B
$63.2M 2.11%
1,249,068
-1,585,001
-56% -$75.9M
BCYC
19
Bicycle Therapeutics
BCYC
$269M
$63.1M 2.11%
3,490,506
– –
GERN icon
20
Geron
GERN
$828M
$62.4M 2.08%
29,583,449
+3,883,449
+15% +$7.55M
EDIT icon
21
Editas Medicine
EDIT
$396M
$55.4M 1.85%
5,473,086
-1,628,849
-23% -$14.3M
AMAM
22
DELISTED
Ambrx Biopharma Inc
AMAM
$52.8M 1.76%
+3,710,412
New +$42.2M
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.57B
$48.2M 1.61%
+500,000
New +$48M
TRML
24
DELISTED
Tourmaline Bio
TRML
$47.5M 1.59%
+1,815,854
New +$36.3M
HLVX
25
DELISTED
HilleVax
HLVX
$46.5M 1.55%
2,900,000
– –
1
2 3 4

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Deep Track Capital held 78 positions worth $2.99B, up 16% from $2.59B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Deep Track Capital's Q4 2023 filing shows 15 new, 15 increased, 16 reduced and 18 closed positions. Its largest new stake was argenx: 300,000 shares worth $114M. The largest sale was Jazz Pharmaceuticals, an estimated $136M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

  • Deep Track Capital's largest Q4 2023 buy was argenx: 300,000 shares worth $114M.
  • Deep Track Capital added most to Guardant Health in Q4 2023, an estimated $24.9M increase.
  • Deep Track Capital's biggest Q4 2023 reduction was Jazz Pharmaceuticals, cutting an estimated $136M.
  • Deep Track Capital fully exited NovoCure in Q4 2023, selling an estimated $40.4M.
  • Deep Track Capital's ten largest holdings make up 41% of its $2.99B portfolio in Q4 2023.
  • Deep Track Capital opened 15 new positions and closed 18 in Q4 2023.
  • Deep Track Capital's portfolio value rose 16% quarter-over-quarter to $2.99B.

Based on Deep Track Capital's 13F filing for Q4 2023, filed 14 Feb 2024.